BioLineRx Ltd. (NASDAQ:BLRX) posted its earnings results on Tuesday. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05), MarketWatch Earnings reports.

Shares of BioLineRx (BLRX) traded up 2.63% during mid-day trading on Tuesday, hitting $1.17. The stock had a trading volume of 421,397 shares. The stock’s 50-day moving average is $0.90 and its 200 day moving average is $0.96. The firm’s market cap is $72.28 million. BioLineRx has a 12 month low of $0.75 and a 12 month high of $1.42.

A number of analysts have weighed in on BLRX shares. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Tuesday, April 18th. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “sell” rating in a report on Tuesday, June 20th. Maxim Group upgraded BioLineRx from a “hold” rating to a “buy” rating and upped their target price for the stock from $1.00 to $3.00 in a report on Thursday, May 18th. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Oppenheimer Holdings, Inc. started coverage on BioLineRx in a report on Friday. They set an “outperform” rating and a $3.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $2.59.

Several institutional investors have recently bought and sold shares of BLRX. Citadel Advisors LLC increased its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of BioLineRx during the first quarter worth approximately $126,000. Benchmark Capital Advisors increased its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the last quarter. KCG Holdings Inc. increased its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in shares of BioLineRx during the first quarter worth approximately $3,018,000. Institutional investors and hedge funds own 34.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/biolinerx-ltd-nasdaqblrx-announces-earnings-results.html.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Earnings History for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.